Table 1.
Patient | Session | Age | Sex | Medication | DBS parameters | Trial duration |
N trials | Preimplantation UPDRS-Part III |
T | B | R |
---|---|---|---|---|---|---|---|---|---|---|---|
+2 | 55 | M | normal acting l-Dopa at +26 min and fast acting l-Dopa at +43 min |
3 mA | 7.5 s | 144 | 25 (med-on) | 0 | +2 | +2 | |
c | fast acting l-Dopa at +15 min | 2.4 mA, bi | 216 | n/a | |||||||
+2 | 54 | F | medication off | 6 mA | 6 s | 144 | 18 | +2 | +2 | +2 | |
c | 168 | +3 | 0 | +2 | |||||||
c | 56 | M | medication off | 6 mA | 7.5 s | 120 | 41 | n/a | |||
+2 | retarded l-Dopa at −150 min | 6.5 mA | 6 s | 168 | 23 | 0 | 0 | +1 | |||
+3 | 44 | M | retarded l-Dopa at −330 min | 5 mA | 168 | 0 | 0 | +1 | |||
c | normal acting l-Dopa combined with COMT-Inhibitor (Entacapone) at −210 min |
3.5 mA, 30 μs | 156 | 0 | +1 | +2 | |||||
+2 | retarded l-Dopa at −300 min | 6.5 mA | 6 s | 144 | 33 | 0 | +1 | +1 | |||
+3 | 69 | M | retarded l-Dopa at −210 min | 6.5 mA | 144 | +1 | +1 | +2 | |||
c | normal acting l-Dopa −660 min | 6.0 mA | 192 | 0 | +1 | +1 | |||||
+2 | 63 | M | retarded l-Dopa at −330 min | 3 mA | 9 s | 144 | 35 | +1 | +2 | 0 | |
c | medication off | 3.5 mA | 192 | 0 | +2 | +1 | |||||
+2 | n/a | 4.5 mA | 9 s | 168 | 34 | 0 | 0 | +2 | |||
+3 | 55 | M | retarded l-Dopa at −330 min | 5 mA | 6 s | 168 | n/a | ||||
c | normal acting l-Dopa −660 min | 3.5 mA | 7.5 s | 192 | 0 | +2 | +2 |